SCHEMBL5111570

SCHEMBL5111570

CC1OC(=O)Nc2cccc(Cl)c21

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR5A P47898 8/20 0.46
▸ HTR1A P08908 6/20 0.46
▸ HTR2C P28335 6/20 0.46
▸ HTR7 P34969 6/20 0.46
▸ HTR1D P28221 5/20 0.46
▸ HTR2A P28223 2/20 0.46
▸ HTR6 P50406 2/20 0.46
▸ HTR3A P46098 1/20 0.46
▸ HRH1 P35367 1/20 0.46
▸ PBRM1 Q86U86 4/20 0.40
▸ SMARCA2 P51531 2/20 0.40
▸ SMARCA4 P51532 2/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ BRD4 O60885 5/20 0.39
▸ CREBBP Q92793 5/20 0.39
▸ CES1 P23141 1/20 0.39
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119433 0.80 HTR5A (0.47) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL5118402 0.76 PBRM1 (0.38) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL24112728 0.75 HTR5A (0.51) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL24112229 0.75 HTR5A (0.51) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL5111692 0.74 PDE3B (0.34) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL18128085 0.73 PARP1 (0.56) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL31402319 0.73 PARP1 (0.56) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL5117969 0.73 PBRM1 (0.41) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL24740178 0.72 HTR5A (0.45) HTR5AHTR1AHTR2CHTR7HTR1D
SCHEMBL24019656 0.72 HTR5A (0.45) HTR5AHTR1AHTR2CHTR7HTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442696-B2 Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses LIGAND PHARMACEUTICALS, INC. (US) 2008-10-28 — — US disclosed
US-20070197520-A1 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES LIGAND PHARMACEUTICALS INC. 2007-08-23 — — US disclosed
WO-2006010142-A2 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE LIGAND PHARMACEUTICALS, INC. (US) 2006-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197520-A1 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES NR3C2, MC2R, NR3C1 HTR5A 268/4885HTR1A 766/4885HTR2C 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback